Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings (MEDP) is a leading global clinical research organization accelerating drug development through full-service trial management. This page provides investors and industry professionals with timely updates on MEDP's clinical trial milestones, regulatory developments, and strategic partnerships.
Access official press releases and curated analysis covering key operational areas including therapeutic research advancements, bioanalytical innovations, and global trial management. Our repository ensures transparent tracking of MEDP's progress in oncology, cardiology, and rare disease research sectors.
Discover updates across critical categories: quarterly financial results, FDA submission announcements, international trial initiations, and executive leadership changes. All content is verified through primary sources to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of MEDP's role in advancing clinical research. For real-time updates, consider enabling notifications or subscribing to our institutional research alerts.
Medpace Holdings (MEDP) reported Q1 2025 financial results with revenue reaching $558.6 million, a 9.3% increase from $511.0 million in the prior year. GAAP net income rose to $114.6 million ($3.67 per diluted share), up from $102.6 million ($3.20 per diluted share) year-over-year.
The company's backlog decreased 2.1% to $2.85 billion, with net new business awards of $500.0 million resulting in a book-to-bill ratio of 0.90x. EBITDA grew 2.6% to $118.6 million with a 21.2% margin.
During Q1, Medpace repurchased 1.19 million shares for $389.8 million and received board approval for an additional $1.0 billion share repurchase program. The company projects 2025 revenue between $2.14-2.24 billion, representing 1.5-6.2% growth, with GAAP net income forecast at $378.0-402.0 million.
Medpace Holdings (Nasdaq: MEDP) has announced it will release its first quarter 2025 financial results after market close on Monday, April 21, 2025. The company will hold a conference call to discuss these results on Tuesday, April 22, 2025, at 9:00 a.m. ET.
Participants must pre-register through a provided link to join the conference call. A unique PIN and dial-in number will be provided upon registration. It is recommended to join 10 minutes before the event start. The webcast will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available prior to the call.
Medpace Holdings (MEDP) reported Q4 2024 financial results with revenue increasing 7.7% to $536.6 million. Net new business awards were $529.7 million, representing a net book-to-bill ratio of 0.99x. GAAP net income rose significantly to $117.0 million ($3.67 per diluted share), with a net income margin of 21.8%.
For full-year 2024, revenue grew 11.8% to $2,109.1 million, with net new business awards of $2,230.0 million and a book-to-bill ratio of 1.06x. The company's backlog increased 3.2% to $2,902.2 million. EBITDA increased 32.5% to $480.2 million.
Looking ahead, Medpace provided 2025 guidance projecting revenue between $2.110-2.210 billion and GAAP net income of $378.0-402.0 million. The company also announced a $600 million increase to its stock repurchase program.
Medpace Holdings (MEDP) has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on Monday, February 10, 2025. The company will host a conference call on Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss the results.
Participants must pre-register through a provided link to join the conference call. A webcast of the call will be available in the 'Investors' section of Medpace's website, with a replay accessible approximately one hour after the call ends. A supplemental slide presentation will also be available on the website before the call begins.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q3 2024. Revenue increased 8.3% to $533.3 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $96.4 million, or $3.01 per diluted share, representing a net income margin of 18.1%. EBITDA grew 31.7% to $118.8 million, with an EBITDA margin of 22.3%.
Key highlights include:
- Net new business awards of $533.7 million
- Net book-to-bill ratio of 1.00x
- Backlog increased 8.8% to $2,927.4 million
- Cash and cash equivalents of $656.9 million
For full-year 2024, Medpace forecasts revenue between $2.090 billion and $2.130 billion, representing growth of 10.8% to 12.9% over 2023.
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced that it will release its third quarter 2024 financial results after the market closes on Monday, October 21, 2024. The company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, interested parties must register in advance using the provided link. Upon registration, participants will receive a confirmation email with dial-in details and a unique PIN. The company recommends joining 10 minutes before the event start.
A webcast of the call will be available in the "Investors" section of Medpace's website, with a replay accessible approximately one hour after the call ends. Additionally, a supplemental slide presentation will be available on the website prior to the call.
Medpace Holdings, Inc. (MEDP) reported strong financial results for Q2 2024. Revenue increased 14.6% to $528.1 million, with a backlog conversion rate of 18.2%. GAAP net income rose to $88.4 million, or $2.75 per diluted share, up from $61.1 million in Q2 2023. The company's net income margin improved to 16.7%, while EBITDA grew 34.2% to $112.3 million.
Medpace's backlog increased 13.7% to $2,924.9 million, and net new business awards were $551.0 million, resulting in a net book-to-bill ratio of 1.04x. The company updated its 2024 financial guidance, forecasting revenue between $2.125 billion and $2.175 billion, representing 12.7% to 15.3% growth over 2023.
Medpace Holdings will announce its Q2 2024 financial results post-market on July 22, 2024.
A conference call to discuss the results is scheduled for July 23, 2024, at 9:00 a.m. ET.
Participants must register in advance via a provided link, and step-by-step access details will be sent by email.
The call can also be accessed through a webcast on Medpace's investor site, where a replay and supplemental slide presentation will be available post-call.
Medpace is traded under the ticker MEDP on Nasdaq.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
